Abstract No. 9555 Phase 1b/2, Open Label, Multicenter Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870).

by Michael Persons | Jun 1, 2019 | Immunomodulation, Publications and Presentations